Stock BRPA NRX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Delayed Nasdaq
Other stock markets
 04:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
3.32 USD +4.40% Intraday chart for NRx Pharmaceuticals, Inc. -6.21% -27.83%
Jun. 03 Certain Warrant of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024. CI
Jun. 03 Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
CI
NRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data
DJ
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results
CI
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
MT
Top Premarket Decliners
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
CI
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
CI
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
CI
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
CI
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
CI
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression
CI
NRx Pharmaceuticals Gets Fast-Track Designation for NRX-101 UTI Treatment
DJ
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
CI
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
CI
NRx Pharmaceuticals, Inc. agreed to Spin-Off 50% stake in HOPE Therapeutics, Inc.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. News NRx Pharmaceuticals, Inc.
  5. Highlights